---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-144540"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T07:01:05.647840+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Palvella posts April 2026 corporate presentation; no material updates disclosed

## Summary
- Presentation titled 'First-in-disease therapies for patients with rare diseases'.
- Filing does not contain specific financial or clinical data points.
- No changes to business outlook, guidance, or pipeline disclosed.
- Presentation is intended for investor meetings; no material new information provided.

## SEC filing metadata
- accession: 0001193125-26-144540
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000119312526144540/0001193125-26-144540-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000119312526144540/pvla-20260407.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-144540
- JSON: https://secwatch.observer/filing/0001193125-26-144540.json
- Plain text: https://secwatch.observer/filing/0001193125-26-144540.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.